Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016

Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016
Published Jun 30, 2016
41 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016, provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics.

The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nonstructural Protein 4B (NS4B)
- The report reviews Nonstructural Protein 4B (NS4B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nonstructural Protein 4B (NS4B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nonstructural Protein 4B (NS4B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nonstructural Protein 4B (NS4B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mer

  
Source:
Document ID
GMDHC0139TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Nonstructural Protein 4B (NS4B) Overview61
Therapeutics Development73
  Nonstructural Protein 4B (NS4B) Products under Development by Stage of Development71
  Nonstructural Protein 4B (NS4B) Products under Development by Therapy Area81
  Nonstructural Protein 4B (NS4B) Products under Development by Indication91
Nonstructural Protein 4B (NS4B) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Nonstructural Protein 4B (NS4B) Products under Development by Companies122
Nonstructural Protein 4B (NS4B) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Nonstructural Protein 4B (NS4B) Companies Involved in Therapeutics Development205
  Gilead Sciences, Inc.201
  GlaxoSmithKline Plc211
  Inovio Pharmaceuticals, Inc.221
  Johnson &Johnson231
  Merck &Co., Inc.241
Nonstructural Protein 4B (NS4B) Drug Profiles258
  GSK-8853 Drug Profile251
  INO-8000 Drug Profile262
  PTC-512 Drug Profile281
  PTC-725 Drug Profile291
  PTC-971 Drug Profile301
  Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections Drug Profile311
  Small Molecule to Inhibit NS4B Protein for HCV Drug Profile321
Nonstructural Protein 4B (NS4B) Dormant Projects331
Nonstructural Protein 4B (NS4B) Discontinued Products341
Nonstructural Protein 4B (NS4B) Featured News &Press Releases355
  Apr 27, 2016: Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial351
  Oct 21, 2013: Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial351
  Jan 09, 2013: Inovio Pharma To Initiate Clinical Trial For Hepatitis C Therapeutic Vaccine361
  Oct 26, 2009: Wellcome Trust funds dengue fever research in Leuven371
  Aug 10, 2009: PTC Therapeutics Announced Achievement Of Major Milestone In Schering-Plough Hepatitis C Collaboration381
  Mar 20, 2006: Schering-Plough And PTC Therapeutics Announced Collaboration For Development Of PTC's Preclinical Hepatitis C Compounds382
Appendix402
  Methodology401
  Coverage401
  Secondary Research401
  Primary Research401
  Expert Panel Validation401
  Contact Us401
  Disclaimer411

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Nonstructural-Protein-4B-NS4B-Pipeline-Review-H1-2016-2088-16077>
  
APA:
Global Markets Direct - Market Research. (2016). Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Nonstructural-Protein-4B-NS4B-Pipeline-Review-H1-2016-2088-16077>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.